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Abstract
Background We have developed a novel compound from
acetylsalicylic acid (ASA) and 2-amino-2-(hydrox-
ymethyl)-1,3-propanediol (Tris) precursors with ASA-like
anti-inflammatory efficacy and reduced the mucosa-dam-
aging side-effects. Our aim was to examine local and
remote consequences of ASA-Tris administration in 2-,4-
,6-trinitrobenzene-sulfonic acid (TNBS)-induced colitis as
compared to ASA or mesalamine (5-aminosalicylate)
treatment.
Methods Sprague–Dawley rats were randomized to five
groups (n = 6, each), and TNBS enemas were performed.
Group 1 was the negative control; group 2 was the
untreated colitis group. 12 hour after colitis induction
repeated doses of ASA, ASA-Tris (both 0.55 mmol/kg)
and mesalamine (0.77 mmol/kg) were given 3 times daily
for 3 days to groups 3–5. On day 3 of colitis, the in vivo
histology of the colon and stomach was investigated. Tis-
sue xanthine-oxidoreductase, myeloperoxidase, nitrite/
nitrate changes, and circulating TNF-alpha levels were
measured. In addition, liver mitochondria were examined
with high-resolution respirometry to analyze alterations in
the electron transport chain.
Results TNBS enema significantly elevated inflammatory
enzyme activities, NO production, TNF-alpha concentra-
tion, and induced morphological damage in the colon.
ASA-treatment reduced the inflammatory marker levels
and mucosal injury in the colon, but gastric tissue damage
was present. ASA-Tris- and mesalamine-treatments sig-
nificantly reduced the cytokine levels, inflammatory
enzyme activities, and colonic mucosal damage without
inducing gastric injury. Also, ASA significantly reduced
the Complex IV-linked respiration of liver mitochondria,
which was not observed after ASA-Tris-treatment.
Conclusion As compared to ASA, ASA-Tris conjugation
provides significant protection against the colonic injury
and cytokine-mediated progression of inflammatory events
in experimental colitis without influencing the gastric
epithelial structure.
Keywords TNBS colitis  Gastritis  Non-steroidal
anti-inflammatory drugs  Acetylsalicylic-acid 
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Introduction
Inflammatory bowel diseases (IBDs) are accompanied by
local and systemic immune responses with the recruitment
of effector cells and the release of humoral mediators,
which collectively enhance the breakdown of the mucosal
barrier (Appleyard et al. 2002; Hatoum et al. 2003; Hatoum
and Binion 2005). Indeed, current treatment strategies of
IBD are based on immune modulators, anti-inflammatory
compounds and the use of anti-cytokine agents, including
tumour necrosis factor-a (TNF-a) blockers (Rutgeerts et al.
2004). Non-steroidal anti-inflammatory drugs (NSAIDs)
are also considered as useful additional medication for IBD
patients, mostly with extraintestinal, musculoskeletal dis-
orders (Jose and Heyman 2008). However, each of these
therapies can cause potentially severe side effects, and
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questions on their tolerability have also been emerged
(Blackburn et al. 2002; Donihi et al. 2006; Hasselgren et al.
2010). NSAID administration is no exception; and the
increased risk of gastrointestinal (GI) mucosal injuries,
ulcerative damages after regular, long-term use is well
recognized.
Earlier studies from our laboratory demonstrated that
acetylsalicylic acid (ASA) chemically combined with tris-
hydroxymethyl-aminomethane (Tris) exhibits strong
bioactivity against inflammation and has a less harmful
effect on the gastric mucosa than the original ASA (Varga
et al. 2016). The administration of the novel 2-(acetyloxy)-
N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-benzamide
(ASA-Tris) compound resulted in sustained and prolonged
anti-inflammation and anti-nociception effects in car-
rageenan-induced arthritis in rats and simultaneously
prevented the injury of microvascular structures and the
accumulation of polymorphonuclear leukocytes within the
gastric tissues (Varga et al. 2016). Using this as a basis, we
hypothesized that this approach might provide a thera-
peutic benefit in experimental colitis as well. Hence, our
first goal was to characterize the local and distant effects of
ASA-Tris and ASA treatments in 2,4,6-trinitrobenzene
sulfonic acid (TNBS)-induced colon damage, a commonly
used murine IBD model in preclinical efficacy studies. To
draw meaningful conclusions, positive controls were
incorporated into the protocol. Mesalamine, a 5-aminosal-
icylic acid compound (5-aminosalicylate, or 5-ASA)
(Managlia et al. 2013), is often used as the first line of
therapy of IBD (Braus and Elliott 2009). It acts locally in
the bowel and as a result it has relatively few systemic side
effects (Bickston and Cominelli 2003). With this in mind,
the local, colonic and distant, gastric effects of mesalamine
treatment were also investigated and compared to assess
the therapeutic potential of ASA-Tris.
The pathway bywhich intestinal tissue damage evolves in
IBD is still not known, but it appears that a perturbed mito-
chondrial oxidative phosphorylation (OxPhos) is an
important contributing factor in the pathomechanism of the
disease. In IBD patients the colonic mucosa is often char-
acterized by lower adenosine triphosphate (ATP) levels, and
significantly decreased mitochondrial Complex II activity
was also detected (Kameyama et al. 1984; Santhanam et al.
2012). It was also shown that TNBS administration causes
significant structural damage of epithelial mitochondria with
swelling and disruption of the inner membrane (Bou-Fersen
et al. 2008), and a reduced Complex II activity was also
demonstrated in dextran sodium sulphate-induced experi-
mental colitis as well (Santhanam et al. 2012).
Interestingly, in addition to other cellular effects, both
ASA and aminosalicylates may influence mitochondrial
Oxphos and hence modify the energetics of enterocytes
(Madesh and Balasubramanian 1998). Along these lines,
we examined the second hypothesis that ASA-Tris may
influence GI inflammation by alleviating mitochondrial
dysfunction. To this end, we designed in vitro tests using
high resolution respirometry to analyze the effects of ASA
and ASA-Tris on mitochondrial function.
Materials and methods
The synthesis of the compound and the supporting 1H NMR
and HPLC studies were carried out in the Department of
Medical Chemistry, University of Szeged, the procedure and
the structural characterization were described in details in a
previous communication (Varga et al. 2016) (Fig. 1).
Animals
The experimental protocols were carried out in accordance
with EU directive 2010/63 for the protection of animals
used for scientific purposes and they were approved by the
National Scientific Ethical Committee on Animal Experi-
mentation (National Competent Authority) with license
number V./146/2013. This study also complied with the
criteria of the US National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals.
The experiments were performed in two series on a total
of 45 male Sprague–Dawley rats (average weight
200 g ± 10 g), housed in plastic cages in a thermoneutral
environment (21 ± 2 C) with a 12-h dark–light cycle. The
animals were kept on normal laboratory chow and then fed
with a carbohydrate-rich diet (bread rolls) for 3 days prior
to the experiments.
In vivo study to determine the anti-inflammatory
effects of ASA and ASA-Tris treatments
in experimental colitis
Induction of colitis
The animals were deprived of food, but not water, for 12 h
prior to the enemas. Colonic inflammation was induced by
the intracolonic (ic) administration of TNBS (40 mg/kg in
0.25 ml of 25% ethanol) through an 8 cm-long soft plastic
catheter under transient light inhalation anesthesia (Morris
et al. 1989). In sham-operated groups, only the vehicle for
TNBS was administered. The animals were then returned
to their cages and were fed ad libitum with standard lab-
oratory chow.
In vivo detection of tissue damage
The extent of the damage of the gastric and colonic mucosa
was evaluated by means of fluorescence confocal laser
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scanning endomicroscopy (CLSEM, Five1, Optiscan Pty.
Ltd., Melbourne, Victoria, Australia) developed for in vivo
histology. The analysis was performed twice, indepen-
dently by two investigators (GV and NL). The mucosal
surface of the stomach or distal colon (8 cm proximal to
the anus) was surgically exposed and laid flat for exami-
nation. The microvascular structure was recorded after the
iv administration of 0.3 ml of fluorescein isothiocyanate-
dextran (FITC-dextran, 150 kDa, 20 mg/ml solution dis-
solved in saline, Sigma-Aldrich Inc, St. Louis, MO, USA).
The objective of the device was placed onto the mucosal
surface of the descending colon, and confocal imaging was
performed 5 min after dye administration (1 scan/image,
1024 9 512 pixels and 475 9 475 lm per image). The
changes in the mucosal architecture were examined fol-
lowing the topical application of the fluorescent dye
acridine orange (Sigma-Aldrich Inc, St. Louis, MO, USA).
Afterwards, the surplus dye was washed off the mucosal
surface of the colon with saline 2 min before imaging.
Non-overlapping fields of gastric and colon tissues in
colitis group were compared with the samples of ASA-,
ASA-Tris, and mesalamine-treated or control groups using
a semiquantitative scoring system developed for in vivo
histology, as described previously (Kova´cs et al. 2012;
Varga et al. 2016).
Preparation of tissue biopsies
Tissue biopsies kept on ice were homogenized in a phos-
phate buffer (pH 7.4) containing 50 mM of Tris–HCl
(Reanal, Budapest, Hungary), 0.1 mM of EDTA, 0.5 mM
of dithiotreitol, 1 mM of phenylmethylsulfonyl fluoride,
10 lg/ml of soybean trypsin inhibitor and 10 lg/ml of
leupeptin (Sigma-Aldrich GmbH, Germany). The homo-
genate was centrifuged at 4 C for 20 min at 24,000g and
the supernatant was loaded into centrifugal concentrator
tubes (Amicon Centricon-100; 100,000 MW cut-off ultra-
filter). The activity of xanthine oxidoreductase (XOR) was
determined in the ultrafiltered supernatant, while that of
myeloperoxidase (MPO) was measured on the pellet of the
homogenate.
Tissue MPO enzyme activity
The activity of MPO as a marker of tissue leukocyte
infiltration was measured on the pellet of the homogenate
(Kuebler et al. 1996). Briefly, the pellet was resuspended in
a K3PO4 buffer (0.05 M; pH 6.0) containing 0.5% of hexa-
1,6-bis-decyltriethylammonium bromide. After three repe-
ated freeze–thaw procedures, the material was centrifuged
at 4 C for 20 min at 24,000g and the supernatant was used
for MPO determination. Next, 0.15 ml of 3,30,5,50-tetram-
ethylbenzidine (dissolved in DMSO; 1.6 mM) and 0.75 ml
of hydrogen peroxide (dissolved in K3PO4 buffer; 0.6 mM)
were added to 0.1 ml of the sample. The reaction led to the
hydrogen peroxide-dependent oxidation of tetramethyl-
benzidine, which could be detected spectrophotometrically
at 450 nm (UV-1601 spectrophotometer; Shimadzu,
Kyoto, Japan). MPO activities were measured at 37 C;
then the reaction was halted after 5 min by the addition of
0.2 ml of H2SO4 (2 M). The data were expressed in terms
of the protein content.
XOR activity
XOR activity was determined in the ultrafiltered, concen-
trated supernatant by a fluorometric kinetic assay based on
the conversion of pterine to isoxanthopterine in the pres-
ence (total XOR) or absence (xanthine oxidase activity) of
the electron acceptor methylene blue (Beckman et al.
1989).
Measurement of tissue NO products
Nitrite and nitrate (NOx), stable end-products of NO, were
determined in the gastric and intestinal homogenates by the
Griess reaction. This assay depends on the enzymatic
reduction of nitrate to nitrite, which is then converted into a
Fig. 1 Structural formulae of
ASA (Alog p = 1.19;
pKa = 3.5), the developed
ASA-Tris conjugate (Alog
p = -0.701) and mesalamine
(Alog p = 2.5; pKa = 2.5)
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colored azo compound that is detected spectrophotometri-
cally at 540 nm. The total NOx was then calculated and
expressed in terms of lmol/(mg protein) (Moshage et al.
1995).
Plasma TNF-a level measurements
Blood samples (0.5 ml) taken from the inferior caval vein
were collected into precooled, heparizined (100 U/ml)
polypropylene tubes and then centrifuged at 1000g at 4 C
for 30 min and stored at -70 C until assay. The plasma
TNF-a concentration was determined in duplicate by
means of a commercially available enzyme-linked
immunosorbent assay (Quantikine ultrasensitive ELISA kit
for rat TNF-a; Biomedica Hungaria Kft, Budapest, Hun-
gary). The minimum detectable level was less than 5 pg/
ml, and the interassay and intra-assay coefficients of vari-
ation were less than 10%.
Experimental protocol and surgical preparation
In control group 1 (n = 6), the animals received enemas
with a total volume of 0.25 ml containing 25% of ethanol
(the solvent for TNBS). In groups 2, 3, 4 and 5 (n = 6,
each) colitis was induced with a TNBS enema (40 mg/kg).
In groups 3, 4 and 5 repeated doses of ASA (Col ? ASA;
0.55 mmol/kg (100 mg/kg), in a volume of 10 ml/kg; three
times per day for 3 days), ASA-Tris conjugate
(Col ? ASA-Tris; 0.55 mmol/kg (161 mg/kg), in a vol-
ume of 10 ml/kg; three times per day for 3 days), or
mesalamine (Col ? Mes; 0.77 mmol/kg (118 mg/kg), in a
volume of 10 ml/kg; three times per day for 3 days) were
gavaged to the animals 12 h after colitis induction. In a
previous study, the same acute, single-dose ASA-Tris
administrations reduced inflammatory pain as effectively
as ASA in equimolar doses (Varga et al. 2016).
The animals in the control and the non-treated colitis
groups were gavaged with the solvent for ASA (10 ml/kg
buffered 0.11 M of potassium hydroxide).
On day 3, 2 h after the last treatment, the animals were
anesthetized and surgery was performed. For instrumenta-
tion purposes, the animals were placed in a supine position
on heating pads. The trachea and the right jugular vein
were cannulated and after a midline abdominal incision,
the lumen of the stomach and the distal colon was exposed;
then the mucosa was rinsed with saline to remove bowel or
gastric contents. In each group, an in vivo histology of the
colonic and gastric mucosa was performed by CLSEM to
examine the changes in microvasculature and superficial
morphology. At the end of the experiments, full-thickness
tissue samples were taken to measure mucosal biochemical
changes, and venous blood samples were taken to deter-
mine the plasma TNF-a level.
The in vivo experimental protocol used to determine
the mitochondrial effects of ASA and ASA-Tris
treatments
Fifteen animals were randomly allocated to 3 groups
(n = 5, each). Group 1 served as the vehicle-treated con-
trol (10 ml/kg buffered 0.11 M of potassium hydroxide
was given orally three times per day for three consecutive
days). In group 2, ASA solution [0.55 mmol/kg (100 mg/
kg), in a volume of 10 ml/kg; three times per day for
3 days] was gavaged via a flexible oesophageal tube to the
animals. Group 3 was treated with the ASA-Tris conjugate
in equimolar doses to ASA [0.55 mmol/kg (161 mg/kg), in
a volume of 10 ml/kg; three times per day for 3 days].
After the treatments, the animals were then returned to
their cages and were fed ad libitum with a carbohydrate-
rich diet. On day 3, 2 h after the last treatments, the ani-
mals were anaesthetized with sodium pentobarbital
(50 mg/kg ip) and in each group, liver samples were taken
for an analysis of the mitochondrial respiration.
Measurements of mitochondrial function
Changes in respiratory activity and reactive oxygen species
(ROS)-producing capacity of rat-liver mitochondria were
determined with high-resolution respirometry (Oxygraph-
2k respirometer, Oroboros Instruments, Innsbruck, Aus-
tria). Tissue samples taken from the left liver lobes of
anesthetized animals (n = 5, in each group) were homog-
enized with a glass Potter homogenizer, followed by
centrifugation in an isotonic sucrose medium (300 mM
sucrose, 0.2 mM EDTA and 10 mM HEPES, adjusted to
pH 7.4 with KOH at 4 C) using the method of Gnaiger
et al. (2000). After the last centrifugation, mitochondrial
pellets were resuspended in a 3 ml MitOx2 (mitochondrial
respiration) medium and utilized for high-resolution
respirometry.
The respiratory activity of isolated mitochondria
For the respirometric analysis of the mitochondrial oxida-
tive phosphorylation (OxPhos) system, we applied the
Substrate-Uncoupler-Inhibitor Titration (SUIT) protocol.
The rate of Complex I-linked respiration was determined
after the addition of 2 mM of malate and 10 mM of glu-
tamate (state II respiration) and 2.5 mM of ADP (state III
respiration). 10 mM of succinate was added to determine
the Complex I and Complex II state III respiration, along
with 0.5 lM of rotenone for Complex II-linked respiration,
2.5 lM of antimycin A (Complex III inhibitor) and 2 mM
of ascorbate and 20 lM of N,N,N,N-tetramethyl-p-
phenylenediamine (TMPD) for Complex IV-linked respi-
ration. Lastly, 5 lM of Complex IV inhibitor sodium-azid
264 G. Varga et al.
123
was added to the medium. The DatLab software (Oroboros
Instruments) was used for the data analysis, and the
respirometry data were normalized to the mitochondrial
biomass (Hu¨tter et al. 2007).
Mitochondrial ROS production
ROS generation (i.e. superoxide anion radical production)
was estimated from hydrogen peroxide (H2O2) release and
monitored fluorimetrically via the Amplex Red/horseradish
peroxidase system, whereby Amplex Red (non-fluorescent)
becomes oxidized to Resorufin. The calibration of H2O2
production was performed by the addition of known
amounts of H2O2. With this protocol, rat-liver mitochon-
dria were incubated with oxidizing Complex II-substrate
succinate in the presence of respiratory chain inhibitors
(rotenone and antimycin-A). Also using this protocol, the
H2O2 production at Complex I was estimated based on the
reverse electron flux (RET) from Complex II.
Statistical analysis
Data analysis was performed with a statistical software
package (SigmaStat for Windows, Jandel Scientific, Erk-
rath, Germany). Changes in variables within and between
groups were analyzed using two-way repeated measures
ANOVA, followed by the Bonferroni test in those cases of
mitochondrial respiratory function, and H2O2 production.
A Friedman repeated measures analysis of variance on
ranks was applied within groups in the colitis study. Time-
dependent differences from the baseline for each group
were assessed using Dunn’s method. Differences between
groups were analysed with a Kruskal–Wallis one-way
analysis of variance on ranks, followed by Dunn’s method
for a pairwise multiple comparison. In the figures, median
values and 75th and 25th percentiles are given; p values
\0.05 were considered significant.
Results
Colitis study
The severity of colitis was estimated with macroscopic
changes in the stool and the measurement of body weight.
TNBS induction was accompanied by diarrhoea and the
appearance of blood in the faeces in contrast with that in
the control group. On day 3 of TNBS colitis the animals
exhibited a significant weight loss relative to the baseline
body weight (day 0) and the average weight in control
group. ASA-Tris and mesalamine treatments prevented the
weight loss relative to that in the control groups (Fig. 2).
In vivo detection of mucosal injury in the colon
In the vehicle-treated controls, the network of capillaries
exhibited a honeycomb pattern and the luminal openings of
the crypts were covered with a continuous layer of
epithelial cells, which appeared as black holes that opened
onto the surface of the mucosa (Fig. 3a, f; Table 1). The
tissue damage was evident after TNBS enemas. Fluores-
cent dye leakage with edema formation was present 3 days
after TNBS treatments (Fig. 3b) and the complete loss of
the epithelium was commonly observed (Fig. 3g, Table 1).
ASA treatment moderated the severity of injury, but these
changes were still apparent (Figs. 3c, 5h; Table 1). ASA-
Tris (Fig. 3d, i; Table 1) and mesalamine (Fig. 3e, j;
Table 1) treatments prevented the structural changes in the
microvasculature and the loss of epithelium of the inflamed
colonic mucosa.
In vivo detection of mucosal injury in the stomach
In the control group, the network of capillaries and gastric
mucosal epithelium exhibited a normal pattern (M = 0;
p25 = 0; p75 = 0.3; Table 2). The TNBS enema did not
Fig. 2 Changes in body weight between days 1 and 3 of colitis in
control (white empty box), colitis (grey empty box), ASA-treated-
colitis (striped grey box on the left), ASA-Tris-treated colitis (stripped
grey box on the right), mesalamine-treated colitis (checked grey box)
groups. The plots demonstrate the median (horizontal line in the box)
and the 25th (lower whisker) and 75th (upper whisker) percentiles.
*p\ 0.05 within groups vs baseline values, xp\ 0.05 between
groups vs control group, #p\ 0.05 between colitis group vs ASA-Tris
or mesalamine treated groups, &p\ 0.05 between ASA-treated vs
ASA-Tris or mesalamine treated groups
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cause gastritis (M = 0.6; p25 = 0; p75 = 1.7), while sig-
nificant tissue damage was present in the ASA-treated
colitis group in contrast with the control group. The
capillary network was injured and fluorescent dye leakage
suggested increased endothelial permeability which resul-
ted in edema formation and structural tissue damage
(M = 5.3; p25 = 4.8; p75 = 5.7). In the ASA-Tris-treated
group this damage was not present (M = 0; p25 = 0;
p75 = 0.5; Table 2) and also in the case of mesalamine-
treated colitis groups the normal capillary and mucosal
patterns were observed (M = 0; p25 = 0; p75 = 0.4;
Table 2).
MPO and XOR activities and tissue NOx level in the colon
The activity of XOR is one of the most important sources
of reactive oxygen species in the GI tissues that can greatly
increase tissue damage. Another important effect of the
ROS produced by the XOR system is the activation and
local accumulation of neutrophil leukocytes, which can be
investigated by the measurement of tissue MPO enzyme
activity. Activated neutrophils can contribute to the NO
production along with the endothelium. The increased level
of NO and ROS production can further enhance tissue
damage with the formation of peroxynitrite, a highly
oxidative agent with relatively long biological half-life.
The NOx level refers directly to the intensity of NO pro-
duction. The MPO and XOR activities and NOx levels in
the distal colon significantly increased 3 days after colitis
compared to the controls. Two hour after the last ASA-
treatment, the colonic MPO activity was decreased
Fig. 3 Upper panel In vivo histology images of the mucosal surface
of the ascendent colon recorded by confocal laser scanning endomi-
croscopy (CLSEM) after iv administration of FITC-dextran: a the
mucosal vasculature in the control group. b Dye leakage from the
vessel lumina on day 3 of colitis. c Moderate dye leakage from the
vessel lumina on day 3 of colitis and ASA treatment. d Normal
mucosal vasculature on day 3 of colitis and ASA-Tris treatment.
e Normal mucosal vasculature after 3 days of colitis and mesalamine
treatment. Lower panel CLSEM after topical administration of
acriflavine: f the normal structure of the mucosa in the control group.
g The total loss of epithelium on the surface on day 3 of colitis. h The
enlarged spaces between the glands on day 3 of colitis and ASA
treatment. i The normal structure of the mucosa on day 3 of colitis and
ASA-Tris treatment. j The normal structure of the mucosa on day 3 of
colitis and mesalamine treatment
Table 1 The effects of ASA, ASA-Tris or mesalamine treatments on
changes in mucosal structure of the colon and TNF-alpha levels
(pmol/ml)
Tissue damage TNF-alpha level
Control
Median 0.1 75
25p; 75p 0.025; 0.2 59; 80
Colitis
Median 6.0a 148a
25p; 75p 5.5; 6.6 97; 175
Col ? ASA
Median 2.5a,b 55b
25p; 75p 1.875; 3.0 37; 70
Col ? ASA-Tris
Median 0.5b,c 51b
25p; 75p 0.0; 0.5 28.5; 69
Col ? Mes
Median 0.5b,c 55b
25p; 75p 0.0; 1.0 41; 87
a p\ 0.05 between groups vs control group
b p\ 0.05 between ASA, ASA-Tris and mesalamine groups vs col-
itis group
c p\ 0.05 between ASA-Tris and mesalamine groups vs ASA group
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significantly relative to the colitis group. The ASA-Tris and
mesalamine treatments resulted in a significant decrease in
MPO activity as compared with that in the colitis or ASA-
treated colitis groups (Fig. 4a).
ASA treatment did not influence the elevated XOR
activity, but both ASA-Tris and mesalamine treatment
effectively reduced the activation of XOR (Fig. 4b).
In the ASA-treated colitis group, the elevation of NOx
was significantly higher in comparison with the control
group. Both ASA-Tris and mesalamine treatments
decreased the NOx elevation, unlike that in the non-treated
colitis or ASA-treated colitis groups (Fig. 4c).
MPO and XOR enzyme activity and tissue NOx level
in the stomach
On day 3 of colitis, the gastric MPO and XOR activities were
significantly increased in contrast to those in the control group,
while the NOx level did not change in the gastric tissue.
Two hour after the last ASA treatment, the MPO activity
remained significantly elevated relative to that in the con-
trol group. The ASA-Tris and mesalamine treatments
reduced the elevation in the MPO activity in the stomach as
compared to that in the colitis or ASA-treated colitis
groups (Table 2).
ASA treatment did not influence the increased XOR
enzyme activity, while ASA-Tris and mesalamine treat-
ment prevented the elevated activation of XOR enzyme
(Table 2).
In the ASA-treated colitis group, the elevation of NOx
was significantly higher than that in the control group.
ASA-Tris and mesalamine treatments did not increase
NOx, in contrast with that in the ASA-treated colitis group
(Table 2).
Changes in plasma TNF-a level
The source of TNF-a may be the lymphocytes or activated
neutrophil leukocytes. It can further enhance ROS pro-
duction and the release of other proinflammatory cytokines
(Neurath et al. 1997). The importance of TNF-a was
described in the pathogenesis of IBDs and it is a significant
target of the biological therapy of IBDs (Ferrante et al.
2007; Rutgeerts et al. 2004). The plasma level of TNF-a
significantly increased after colitis induction as compared
with that in the control group. The plasma level of TNF-a
in the ASA-treated group with that in decreased relative to
the colitis group. ASA-Tris and mesalamin treatment sig-
nificantly decreased the plasma TNF-a level, in contrast to
that in the non-treated colitis and ASA-treated colitis
groups (Table 1).
Functional mitochondrial changes
Respiratory activity of mitochondria
Basal mitochondrial respiration was induced by adding
substrates of Complex I (Fig. 5). The saturating concen-
tration of ADP resulted in a twofold increase in Complex
I-linked respiration. After a stable signal had been attained,
Complex II-dependent respiration was stimulated by add-
ing succinate, which caused a further 1.5-fold increase in
all the groups. Complex I was then inhibited with rotenone
to assess Complex II-linked respiration. There was a ten-
dency in the ASA group to display lower respiratory values
in Complex I- and II-dependent oxygen consumption, but
these differences were statistically not significant among
the groups.
After Complex III inhibition with antimycin-A, the
residual O2 consumption was identical in all the groups.
However, when ascorbate and TMPD were added to the
medium, Complex IV-linked respiration significantly
decreased in the ASA group as compared with that in the
control and ASA-Tris groups. Next, the inhibition of
Complex IV by adding sodium-azide resulted in signifi-
cantly lower residual respiratory flux in the ASA-treated
group, but in the ASA-Tris group (Fig. 5) this was restored
to the level of the control group.
Table 2 The effects of colitis and ASA, ASA-Tris or mesalamine
treatments on changes in mucosal structure, myeloperoxidase [mU/
(mg protein)], xanthine oxidoreductase enzyme activity [pmol/
(min mg)] and NOx level [nM/(mg protein)] in gastric tissue
Tissue
damage
MPO
activity
XOR
activity
NOx level
Control
Median 0 325 25.8 0.86
25p; 75p 0; 0.3 300; 584 25.1; 26.7 0.84; 0.88
Colitis
Median 0.6 933a 41.4a 0.87
25p; 75p 0; 1.7 850; 1030 28.5; 59.6 0.85; 0.97
Col ? ASA
Median 5.3a 786a 42.6a 1.04a
25p; 75p 4.8; 5.7 611; 1055 39.1; 57.8 0.99; 1.34
Col ? ASA-Tris
Median 0c 342b 27.8bc 0.84c
25p; 75p 0; 0.5 228; 385 25.6; 31.4 0.81; 0.84
Col ? Mes
Median 0c 357b 25.8b,c 0.84c
25p; 75p 0; 0.4 229; 393 25.7; 30.1 0.8; 0.85
a p\ 0.05 between groups vs control group
b p\ 0.05 between colitis group vs ASA-, ASA-Tris- or mesala-
mine-treated groups
c p\ 0.05 between ASA-treated group vs ASA-Tris- or mesalamine-
treated groups
Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without… 267
123
ROS production of mitochondria
In the control group, H2O2 generation with succinate as the
sole substrate was partly inhibited by rotenone; however,
the subsequent addition of antimycin-A resulted in a
fourfold increase in H2O2 formation. From these results, it
seems that in this set-up H2O2 production was linked to the
leakage of electrons at Complex I and Complex III, but
Complex III-linked events were predominant. ASA and
ASA-Tris administrations did not influence mitochondrial
H2O2 production significantly (Fig. 6).
Discussion
The lack of understanding of the aetiology and pathome-
chanism of IBD makes it essential to search for new
treatment modalities that can potentially modulate the
outcome of these diseases. Currently, the role of NSAIDs
in IBD therapy is still uncertain as cyclooxygenase inhi-
bitors can either aggravate or ameliorate the activity of the
disease (Takeuchi et al. 2006; Ding et al. 2014). In addi-
tion, hemorrhagic GI side effects can also often hinder the
use of these compounds. Despite this, NSAIDs are viewed
as helpful additional medication for IBD patients, espe-
cially with musculoskeletal disorders such as peripheral
arthritis or ankylosing spondylitis (Jose and Heyman
2008).
The main goal of this study was to test the therapeutic
potential of ASA-Tris, mesalamine and ASA treatments in
TNBS colitis, a standardized stress induction method
where various degrees of mucosal damage are expected in
different regions of the GI tract. In our protocol, a TNBS
enema caused a significant weight loss and severe mucosal
damage in the colon, increased local inflammatory enzyme
activity and elevated the plasma TNF-a level. The degree
of mucosal injury in the colon and the stomach was
observed in parallel by intravital CLSEM imaging, and the
in vivo histology confirmed a severe loss of the epithelial
Fig. 4 Changes in gastric MPO activity (a), XOR activity (b) and the
level of the NOx (c) in the control (white empty box), colitis (grey
empty box), ASA-treated colitis (striped grey box on the left), ASA-
Tris-treated colitis (stripped grey box on the right), mesalamine
treated colitis (checked grey box) groups. The plots demonstrate the
median (horizontal line in the box) and the 25th (lower whisker) and
75th (upper whisker) percentiles. xp\ 0.05 between groups vs control
group, #p\ 0.05 between colitis group vs ASA-Tris or mesalamine
treated groups, &p\ 0.05 between ASA-treated vs ASA-Tris or
mesalamine treated groups
Fig. 5 Oxygen consumption of liver mitochondria measured by
means of high-resolution respirometry. Animals received ASA
treatment (ASA group, black column) or ASA-Tris treatment (ASA-
Tris group, grey column), or vehicle (control group, white column).
Data are presented as mean ± SEM. #p\ 0.05 vs control group (one-
way ANOVA, Bonferroni test). G glutamate, M malate, D ADP,
S succinate, Rot rotenone, Ama antimycin A, TMPD ascorbate and
TMPD, NaN3 sodium-azide
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cover and an evolving endothelial injury on the surface of
the large intestinal mucosa.
In IBD, the intramural perfusion of the colon is usually
deranged (Laroux and Grisham 2001) and the microcircu-
latory impairment is accompanied by increased cell–cell
interactions (Granger 1999). The activation of ROS-gen-
erating enzymes, such as XOR, leads to an increased ROS
formation and the functional endothelial disorder shifts the
balance between the vasoconstrictor and vasodilator agents
(Palmer et al. 1987; Masaki 1989; Hatoum et al. 2003). The
inflow of polymorphonuclear (PMN) leukocytes in the
villus microcirculation provokes further microvascular
damage (Granger and Kubes 1994) and these changes
together increase the capillary permeability and result in
edema formation (Granger et al. 1988). These character-
istic signs were all detected in the present study; moreover,
the potentially detrimental microvascular alterations were
accompanied by enhanced XOR activity and elevated tis-
sue MPO levels. Furthermore, these changes were
accompanied by increased local NOx concentrations, pro-
viding indirect evidence for evolving oxido-nitrosative
stress in the intestinal tissue. Besides this, the increased
circulating plasma TNF-a concentrations demonstrated the
spreading of inflammatory signals and the systemic aspect
of a local insult. In spite of this, the induction of colitis did
not result in remote injury in the stomach; an in vivo his-
tology demonstrated that the normal mucosal
characteristics and also normal inflammatory enzyme
activities were present in the gastric tissue.
Our previous cross-sectional study demonstrated that
biologically active product can be synthesized from ASA
and Tris precursors with a much less damaging effect on
the gastric mucosa than that with the original ASA (Varga
et al. 2016). In the present study we have extended the
scope of these investigations, and the in vivo histology
provided evidence that ASA treatment does not entirely
prevent the evolution of TNBS-induced injury in the large
intestine. The capillary permeability remained higher and,
simultaneously, increased XOR activity and NOx levels
were detected. ASA-Tris, however, effectively reduced the
weight loss, decreased the level of inflammatory markers in
the colon, and mucosal destruction was also diminished.
The in vivo microscopic observation of the colonic
mucosal surface provided evidence for an intact
microvascular structure, and the effects of the ASA-Tris
conjugate were similar to the efficacy of mesalamine in the
colon on the third day of colitis.
The effects of the treatments were compared and eval-
uated on the gastric mucosa as well. Mesalamine and ASA-
Tris administration did not cause gastric damage and they
did not change the level of inflammatory markers in the
stomach, but the administration of ASA elevated the
oxidative and nitrosative stress markers; and besides this,
tissue injury was observed. The ASA therapy-induced
damage of the gastric mucosal surface was characterized
by the loss of epithelium and accompanied by visible signs
of capillary injury.
The exact molecular background governing the process
of IBD is still poorly understood, but the overproduction of
inflammatory cytokines, including TNF-a is viewed as
fundamental. TNF-a is thought to be largely responsible
for the spreading of local reactions to remote organs, and
the TNF-a blockade has the theoretical advantage of
abrogating the systemic inflammatory response at an earlier
stage and in a specific fashion. In this study the TNBS
colitis elevated the plasma TNF-a level significantly and,
once again this increase was moderated by ASA-Tris
treatment, which is as efficient as mesalamine treatment.
The precise mechanism of action of ASA-Tris is not
known for certain today. Tris is commonly used as a
component of buffer solutions, which is effective between
pH ranges 7.07 and 9.07, and a preferred alternative in
patients with mixed acidosis (Kallet et al. 2000; Hoste et al.
2005). Apart from its influence on acidemia, Tris may
inhibit enzyme activities, such as aminopeptidases and
alpha-amylases (Desmarais et al. 2002; Ghalanbor et al.
2008). Of note, Tris is an important constituent of the
NSAID ketorolac tromethamine salt (ketorolac and Tris
1:1) because it enhances the solubility and bioavailability
(Mroszczak et al. 1987). Based on this background, it
seemed plausible that a new drug synthesized from ASA
and Tris precursors might favourably affect the degree of
Fig. 6 Hydrogen peroxide (H2O2) production of liver mitochondria
measured by means of high-resolution respirometry. Animals
received ASA (ASA group, black column) or ASA-Tris (ASA-Tris
group, grey column), or vehicle (control group, white column). Data
are presented as mean ± SEM. *p\ 0.05 vs S (one-way ANOVA,
Bonferroni test). S succinate, Rot rotenone, Ama antimycin A
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ASA-induced mucosal damage. In our previous study
where the effects of ASA-mono-hydroxymethyl-amino-
methane, ASA-bis-hydroxymethyl-aminomethane and
ASA-Tris derivatives were compared, the degree of effi-
cacy of these compounds was found to be proportional to
the number of hydroxy groups (Varga et al. 2016). This
suggests that there is a redox control mechanism present,
where the alcoholic moiety of ASA-Tris may play an active
role in this process and this presumably leads to a reduction
in membrane damage.
As we mentioned above, the pathways leading to
mucosal destruction are still not well understood, but IBD
is characterized by an energy deficiency state of the colonic
epithelium (Kameyama et al. 1984). It was also shown that
ASA administration may also inhibit mitochondrial respi-
ration and the production of ATP in a concentration-
dependent manner (Spenney and Bhown 1977). Previously,
it was also demonstrated that cyclooxygenase inhibition
opens mitochondrial permeability transition pores, which is
responsible for cytochrome c release, a marker of mito-
chondrial inner membrane damage (Gugliucci et al. 2002).
In the current study, ASA treatment led to mitochondrial
dysfunction involving depressed mitochondrial electron
transport and lower OxPhos capacity. The decreased
electron flux was accompanied by the inhibition of the
activities of respiratory chain enzymes, especially cyto-
chrome c oxidase (Complex IV). The in vitro experimental
data demonstrated the direct effects of ASA-Tris on iso-
lated liver mitochondria. The respiratory complex-specific
H2O2 production was not affected by the compound, but
the ASA-Tris conjugate reduced the disturbances associ-
ated with electron transport and increased the efficacy of
oxygen consumption. Our results, therefore, suggest that
ASA-Tris is not a radical scavenger directly; rather the
favourable effects are probably linked to its protective
potential against oxidative biomembrane damage. This
view is supported by our previous in vivo study, which
showed that ASA increased gastric malondialdehyde levels
in rats, which demonstrates the increased level of mem-
brane lipid peroxidation. What is more, ASA caused an
inhibition of the function of the mitochondrial respiratory
chain, while the same phenomenon was not observed in the
case of the ASA-Tris conjugate (Varga et al. 2016).
In summary, our study has revealed that the ASA-Tris
conjugate significantly decreased the degree of inflamma-
tory damage in the large intestine by targeting local
potentially destructive changes without inducing significant
side-effects on the gastric mucosa. The investigations
explain the anti-inflammatory action at the mitochondrial
level and provide a mechanistic basis for the observations.
The study has certain limitations, as well. TNBS colitis is
accompanied by acute, erosive epithelial injuries, and
therefore, chronic models that are more dependent upon the
adaptive immune system are clearly needed to explain how
the various pharmacologic manipulations affect the
mucosal barrier repair in addition to the inflammatory
response. Nevertheless, our findings suggest that ASA-Tris
might be a promising alternative to NSAID therapy and
may, therefore, be a good option for future therapeutic
investigations of IBD.
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